The interleukin-1 families of cytokines and receptors: Therapeutic potential for immunomodulation and the treatment of inflammatory disorders

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 7, 2006, Pages 879-912

  Dumont, Francis J ^a  

^a NONE   (United States)

Author keywords

Anti inflammatory therapy; Cytokines; Genetic polymorphism; Il 1 family; IL 1 ; IL 1 ; IL 18; IL 1ra; IL 33; Immunostimulation; Immunosuppression; Rheumatoid arthritis

Indexed keywords

EID: 34447557104     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.7.879     Document Type: Review

References (287)

1. DINARELLO CA: Biologic basis for interleukin-1 in disease. Blood (1996) 87:2095-2147. • Seminal review of the early work defining the biology and pathogenic properties of IL-1.
2. DINARELLO CA: Interleukin-1. Cytokine Growth Factor Rev. (1997) 8:253-265.
3. DINARELLO CA: Proinflammatory cytokines. Chest (2000) 118:503-508.
4. AREND WP, MALYAK M, GUTHRIDGE CJ, GABAY C: Interleukin-1 receptor antagonist: role in biology. Ann. Rev. Immunol. (1998) 16:27-55.
5. AREND WP: The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. (2002) 13:323-340. •• This review describes the functional regulation of IL-1 by its natural antagonist in health and disease.
6. NICKLIN MJ, BARTON JL, NGUYEN M et al.: A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics (2002) 79:718-725. •• Along with reference 89, this article describes the order, orientation and intergenic distance of the nine IL-1 family genes that lie within a ∼ 400 kb region on human chromosome 2.
7. GRACIE JA, ROBERTSON SE, MCINNES IB: Interleukin-18. J. Leukoc. Biol. (2003) 73:213-224. • Overview of the biological features of IL-18.
8. MUHL H, PFEILSCHIFTER J: Interleukin-18 bioactivity: a novel target for imunopharmacological anti-inflammatory intervention. Eur. J. Pharmacol. (2004) 500:63-71. •• Critical review of the pathogenic potential and therapeutic modulation of IL-18 bioactivity.
9. DUNN E, SIMS JE, NICKLIN MJ, O'NEILL LA: Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol. (2001) 22:533-536. •• An excellent early summary of the molecular and biological features of IL-1 family cytokines encoded by the IL-1 gene cluster on human chromosome 2.
10. SIMS JE, NICKLIN MJ, BAZAN JF et al.: A new nomenclature for IL-1-family genes. Trends Immunol. (2001) 22:536-537. • Proposes the designation IL-1F5-IL-1F10 as a unifying nomenclature for the novel members of the IL-1 family of cytokines.
11. H2 cytokine production.
12. SIMS JE: IL-1 and IL-18 receptors, and their extended family. Curr. Opin. Immunol. (2002) 14:117-122.
13. SUBRAMANIAM S, STANSBERG C, CUNNINGHAM C: The interleukin 1 receptor family. Dev. Comp. Immunol. (2004) 28:415-428. • Comprehensive review of the structure and biology of the IL-1 receptor family members.
14. LI X, QIN J: Modulation of Toll-interleukin 1 receptor mediated signaling. J. Mol. Med. (2005) 83:258-266.
15. DINARELLO CA: The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. (2002) 20:S10-S13.
16. KORNMAN KS: Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am. J. Clin. Nutr. (2006) 83:475S-483S. •• An overview of sequence variations within the IL1 gene cluster and their association with the inflammatory response and the risk for developing coronary artery disease, Alzheimer's disease, gastric cancer and periodontitis.
17. DUFF GW: Evidence for genetic variation as a factor in maintaining health. Am. J. Clin. Nutr. (2006) 83:431S-435S. •• An overview of sequence variations within the IL1 gene cluster and their association with the inflammatory response and the risk for developing certain diseases in which inflammation plays a role.
18. FURST DE: Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin. Ther. (2004) 26:1960-1975. • Along with reference [217] this article reviews the clinical studies of anakinra in RA and shows that it has a favourable safety profile and beneficial activity.
19. DINARELLO CA: Blocking IL-1 in systemic inflammation. J. Exp. Med. (2005) 201:1355-1359.
20. BRADDOCK M, QUINN A: Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discovery (2004) 3:330-339. •• Review of the rationale and current strategies for the therapeutic modulation of IL-1 bioactivity.
21. BRADDOCK M, QUINN A, CANVIN J: Therapeutic potential of targeting IL-1 and IL-18 in inflammation. Expert Opin. Biol. Ther. (2004) 4:847-860. •• Review of the rationale and current strategies for the therapeutic modulation of IL-1 and IL-18 bioactivities.
22. BURYSKOVA M, POSPISEK M, GROTHEY A, SIMMET T, BURYSEK L: Intracellular interleukin-1α functionally interacts with histone acetyltransferase complexes. J. Biol. Chem. (2004) 279:4017-4026.
23. WERMAN A, WERMAN-VENKERT R, WHITE R et al.: The precursor form of IL-1á is an intracrine proinflammatory activator of transcription. Proc. Natl. Acad. Sci. USA (2004) 101:2434-2439.
24. PALMER G, TROLLIET S, TALABOT-AYER D et al.: Pre-interleukin-1α expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1). Cytokine (2005) 31:153-160.
25. NIKI Y, YAMADA H, KIKUCHI T et al.: Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 α transgenic mice. J. Immunol. (2004) 172:577-584. •• This study demonstrates the pathogenic potential of membrane-associated IL-1α acting via juxtacrine interactions in a mouse model of RA.
26. ZALDIVAR F, NUGENT DJ, IMFELD K, BERMAN MA: Identification of a novel regulatory element in the human interleukin 1 α (IL-1α) gene promoter. Cytokine (2002) 20:130-135. (Pubitemid 35370693)
27. MCDOWELL TL, SYMONS JA, DUFF GW: Human interleukin-1α gene expression is regulated by Sp1 and a transcriptional repressor. Cytokine (2005) 30:141-153. (Pubitemid 40615961)
28. RANDLE JC, HARDING MW, KU G, SCHONHARTING M, KURRLE R: ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin. Investig. Drugs (2001) 10:1207-1209. (Pubitemid 32633564)
29. HERZOG C, KAUSHAL GP, HAUN RS: Generation of biologically active interleukin-1β by meprin B. Cytokine (2005) 31:394-403.
30. BURNS K, MARTINON F, TSCHOPP J: New insights into the mechanism of IL-1β maturation. Curr. Opin. Immunol. (2003) 15:26-30. (Pubitemid 35454188)
31. MARTINON F, TSCHOPP J: Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell (2004) 117:561-574. •• This review outlines the concept of inflammosome as a molecular complex involved in caspase-1 activation and the association of cryopyrin mutations with autoinflammatory disorders.
32. STEHLIK C, LEE SH, DORFLEUTNER A et al.: Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J. Immunol. (2003) 171:6154-6163.
33. YU JW, WU J, ZHANG Z et al.: Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Differ (2006) 13:236-249.
34. MARIATHASAN S, WEISS DS, NEWTON K et al.: Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 440:228-232.
35. KANNEGANTI TD, OZOREN N, BODY-MALAPEL M et al.: Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 440:233-236.
36. MARTINON F, PETRILLI V, MAYOR A, TARDIVEL A, TSCHOPP J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 440:237-241.
37. AGOSTINI L, MARTINON F, BURNS K et al.: NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 20:319-325.
38. STOJANOV S, KASTNER DL: Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr. Opin. Rheumatol. (2005) 17:586-599. (Pubitemid 41527820)
39. 7R plays an important role in mature IL-1β production and release in vivo.
40. 7R is involved in the release of mature IL-1β induced by ATP in activated human monocytes.
41. 2+ entry differentially contribute to the release of IL-1 β and IL-1 α from murine macrophages. J. Immunol. (2003) 170:3029-3036.
42. + release. Am. J. Physiol. Cell Physiol. (2004) 286:C1100-C1108.
43. 2.
44. 7 receptor is dependent on TLR signals and requires NF-κB-driven protein synthesis. J. Immunol. (2005) 175:7611-7622.
45. 7 receptor. J. Immunol. (2005) 175:7623-7634.
46. 7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 β processing and release. J. Immunol. (2004) 172:4987-4994.
47. JOOSTEN LA, NETEA MG, KIM SH et al.: IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA (2006) 103:3298-3303. • Suggests that IL-32 may play a role in RA.
48. NETEA MG, AZAM T, FERWERDA G et al.: IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1β and IL-6 production through a caspase 1-dependent mechanism. Proc. Natl. Acad. Sci. USA (2005) 102:16309-16314. •• Shows that IL-32 activates a pathway for caspase-1 stimulation leading to processing of proIL-1β in activated monocytes and may play a role in Crohn's disease.
49. KHORUTS A, OSNESS RE, JENKINS MK: IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands. Eur. J. Immunol. (2004) 34:1085-1090.
50. SANCHEZ-ALAVEZ M, TABAREAN IV, BEHRENS MM, BARTFAI T: Ceramide mediates the rapid phase of febrile response to IL-1β. Proc. Natl. Acad. Sci. USA (2006) 103:2904-2908. •• Demonstrates that IL-1 can induce a rapid, non-transcription-dependent signalling pathway that leads to ceramide production.
51. BAKER FC, SHAH S, STEWART D et al.: Interleukin 1β enhances non-rapid eye movement sleep and increases c-Fos protein expression in the median preoptic nucleus of the hypothalamus. Am. J. Physiol. Reg. Integr. Comp. Physiol. (2005) 288:R998-R1005.
52. BAJAYO A, GOSHEN I, FELDMAN S et al.: Central IL-1 receptor signaling regulates bone growth and mass. Proc. Natl. Acad. Sci. USA (2005) 102:12956-12961.
53. WEI S, KITAURA H, ZHOU P, ROSS FP, TEITELBAUM SL: IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. (2005) 115:282-290.
54. GOSHEN I, YIRMIYA R, IVERFELDT K, WEIDENFELD J: The role of endogenous interleukin-1 in stress-induced adrenal activation and adrenalectomy-induced adrenocorticotropic hormone hypersecretion. Endocrinology (2003) 144:4453-4458.
55. MATSUKI T, HORAI R, SUDO K, IWAKURA Y: IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. (2003) 198:877-888.
56. SOMM E, CETTOUR-ROSE P, ASENSIO C et al.: Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia (2006) 49:387-393.
57. IWAKURA Y: Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. (2002) 13:341-355.
58. BASU A, KRADY JK, LEVISON SW: Interleukin-1: a master regulator of neuroinflammation. J. Neurosci. Res. (2004) 78:151-156.
59. ALLAN SM, TYRRELL PJ, ROTHWELL NJ: Interleukin-1 and neuronal injury. Nat. Rev. Immunol. (2005) 5:629-640.
60. SECKINGER P, LOWENTHAL JW, WILLIAMSON K, DAYER JM, MACDONALD HR: A urine inhibitor of interleukin 1 activity that blocks ligand binding. J. Immunol. (1987) 139:1546-1549.
61. EISENBERG SP, EVANS RJ, AREND WP et al.: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature (1990) 343:341-346. (Pubitemid 20032849)
62. WILSON HL, FRANCIS SE, DOWER SK, CROSSMAN DC: Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. J. Immunol. (2004) 173:1202-1208.
63. GARAT C, AREND WP: Intracellular IL-1Ra Type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-κB pathways. Cytokine (2003) 23:31-40.
64. BANDA NK, GUTHRIDGE C, SHEPPARD D et al.: Intracellular IL-1 receptor antagonist Type 1 inhibits IL-1-induced cytokine production in keratinocytes through binding to the third component of the COP9 signalosome. J. Immunol. (2005) 174:3608-3616.
65. MERHI-SOUSSI F, BERTI M, WEHRLE-HALLER B, GABAY C: Intracellular interleukin-1 receptor antagonist Type 1 antagonizes the stimulatory effect of interleukin-1α precursor on cell motility. Cytokine (2005) 32:163-170.
66. SCHRODER AK, VON DER OHE M, FLEISCHER D, RINK L, UCIECHOWSKI P: Differential synthesis of two interleukin-1 receptor antagonist variants and interleukin-8 by peripheral blood neutrophils. Cytokine (2005) 32:246-253.
67. KIM SH, AZAM T, NOVICK D et al.: Identification of amino acid residues critical for biological activity in human interleukin-18. J. Biol. Chem. (2002) 277:10998-11003. • Demonstrates that Glu-42 and Lys-89 are critical for the structural integrity of IL-18 and for its binding to IL-18R, signal transduction and neutralisation by IL-18BP.
68. 7 receptor polymorphism impairs extracellular adenosine 5′-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun. (2004) 5:588-591.
69. SUGAWARA S, UEHARA A, NOCHI T et al.: Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. (2001) 167:6568-6575.
70. NIYONSABA F, USHIO H, NAGAOKA I, OKUMURA K, OGAWA H: The human β-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J. Immunol. (2005) 175:1776-1784.
71. BUFLER P, GAMBONI-ROBERTSON F, AZAM T, KIM SH, DINARELLO CA: Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem. J. (2004) 381:503-510.
72. SEKIYAMA A, UEDA H, KASHIWAMURA S et al.: A stress-induced, superoxide-mediated caspase-1 activation pathway causes plasma IL-18 upregulation. Immunity (2005) 22:669-677.
73. H2 immune responses in the absence of IL-12.
74. SUGIMOTO T, ISHIKAWA Y, YOSHIMOTO T et al.: Interleukin 18 acts on memory T helper cells Type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J. Exp. Med. (2004) 199:535-545.
75. DAI SM, MATSUNO H, NAKAMURA H, NISHIOKA K, YUDOH K: Interleukin-18 enhances monocyte tumor necrosis factor α and interleukin-1β production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum. (2004) 50:432-443.
76. JOOSTEN LA, SMEETS RL, KOENDERS MI et al.: Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am. J. Pathol. (2004) 165:959-967. • This study shows that local overexpression of IL-18 in murine joint induces a recruitment of inflammatory cells and the production of IL-1 causing cartilage proteoglycan loss.
77. HORWOOD NJ, ELLIOTT J, MARTIN TJ, GILLESPIE MT: IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. (2001) 166:4915-4921.
78. DAI SM, NISHIOKA K, YUDOH K: Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 β and tumour necrosis factor α. Ann. Rheum. Dis. (2004) 63:1379-1386.
79. SEKIYAMA A, UEDA H, KASHIWAMURA S et al.: A role of the adrenal gland in stress-induced up-regulation of cytokines in plasma. J. Neuroimmunol. (2006) 171:38-44.
80. SMITH DE, RENSHAW BR, KETCHEM RR et al.: Four new members expand the interleukin-1 superfamily. J. Biol. Chem. (2000) 275:1169-1175.
81. BUSFIELD SJ, COMRACK CA, YU G et al.: Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics (2000) 66:213-216.
82. MULERO JJ, NELKEN ST, FORD JE: Organization of the human interleukin-1 receptor antagonist gene IL1HY1. Immunogenetics (2000) 51:425-428. (Pubitemid 30265032)
83. DEBETS R, TIMANS JC, HOMEY B et al.: Two novel IL-1 family members, IL-1δ and IL-1ε, function as an antagonist and agonist of NF-κB activation through the orphan IL-1 receptor-related protein 2. J. Immunol. (2001) 167:1440-1446.
84. BARTON JL, HERBST R, BOSISIO D, HIGGINS L, NICKLIN MJ: A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities. Eur. J. Immunol. (2000) 30:3299-3308.
85. DUNN EF, GAY NJ, BRISTOW AF et al.: High-resolution structure of murine interleukin 1 homologue IL-1F5 reveals unique loop conformations for receptor binding specificity. Biochemistry (2003) 42:10938-10944.
86. TOWNE JE, GARKA KE, RENSHAW BR, VIRCA GD, SIMS JE: Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-κB and MAPKs. J. Biol. Chem. (2004) 279:13677-13688.
87. KUMAR S, HANNING CR, BRIGHAM-BURKE MR et al.: Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production. Cytokine (2002) 2002:61-71.
88. PAN G, RISSER P, MAO W et al.: IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine (2001) 13:1-7.
89. TAYLOR SL, RENSHAW BR, GARKA KE, SMITH DE, SIMS JE: Genomic organization of the interleukin-1 locus. Genomics (2002) 79:726-733. •• Along with reference 6, describes the order, orientation and intergenic distance of the nine IL-1 family genes that lie within an ∼ 400 kb region on human chromosome 2.
90. BUFLER P, AZAM T, GAMBONI-ROBERTSON F et al.: A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. USA (2002) 99:13723-13728.
91. GAO W, KUMAR S, LOTZE MT et al.: Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J. Immunol. (2003) 170:107-113.
92. WANG P, MEINHARDT B, ANDRE R et al.: The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1β signalling responses. Cytokine (2005) 29:245-250.
93. KUMAR S, MCDONNELL PC, LEHR R et al.: Identification and initial characterization of four novel members of the interleukin-1 family. J. Biol. Chem. (2000) 275:10308-10314. (Pubitemid 30202089)
94. BERGLOF E, ANDRE R, RENSHAW BR et al.: IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J. Neuroimmunol. (2003) 139:36-43.
95. LIN H, HO AS, HALEY-VICENTE D et al.: Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J. Biol. Chem. (2001) 276:20597-20602. (Pubitemid 37411146)
96. BENSEN JT, DAWSON PA, MYCHALECKYJ JC, BOWDEN DW: Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J. Interferon Cytokine Res. (2001) 21:899-904. (Pubitemid 34048715)
97. CASADIO R, FRIGIMELICA E, BOSSU P et al.: Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/IL-1R(I) complex. FEBS Lett. (2001) 499:65-68.
98. VIGERS GP, DRIPPS DJ, EDWARDS CK, BRANDHUBER BJ: X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor Type 1. J. Biol. Chem. (2000) 275:36927-36933.
99. JENSEN LE, MUZIO M, MANTOVANI A, WHITEHEAD AS: IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J. Immunol. (2000) 164:5277-5286.
100. SMITH DE, HANNA R, FRIEND D et al.: The soluble form of IL-1 receptor accessory protein enhances the ability of soluble Type II IL-1 receptor to inhibit IL-1 action. Immunity (2003) 18:87-96. • Demonstrates that sIL-1RAcP increases the binding of IL-1α and IL-1β to sIL-1RII by ∼ 100-fold, which suggests that sIL-1RAcP contributes to the antagonism of IL-1 action by sIL-1RII.
101. JENSEN LE, WHITEHEAD AS: Expression of alternatively spliced interleukin-1 receptor accessory protein mRNAs is differentially regulated during inflammation and apoptosis. Cell. Signal. (2003) 15:793-802.
102. DUNNE A, O'NEILL LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE (2003) 171:re3.
103. JANSSENS S, BEYAERT R: Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell (2003) 11:293-302.
104. LI S, STRELOW A, FOMTANA EJ, WESCHE H: IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc. Natl. Acad. Sci. USA (2002) 99:5567-5572.
105. DIDIERLAURENT A, BRISSONI B, VELIN D et al.: Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell. Biol. (2006) 26:735-742.
106. JIANG Z, JOHNSON HJ, NIE H et al.: Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through its interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 6 (TRAF6) complex. J. Biol. Chem. (2003) 278:10952-10956.
107. FUNAKOSHI-TAGO M, TAGO K, ANDOH K et al.: Functional role of c-Src in IL-1-induced NF-κ B activation: c-Src is a component of the IKK complex. J. Biochem. (2005) 137:189-197. (Pubitemid 40502395)
108. JALAL DI, KONE BC: Src activation of NF-κB augments IL-1β-induced nitric oxide production in mesangial cells. J. Am. Soc. Nephrol. (2006) 17:99-106.
109. DAVIS CN, MANN E, BEHRENS MM et al.: MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc. Natl. Acad. Sci. USA (2006) 103:2953-2958. •• This paper describes the generation of bifunctional TIR mimetics that inhibit MyD88 function and demonstrates that IL-1β-mediated activation of Src is MyD88-dependent, whereas the activation of PI3K is MyD88 independent.
110. NEUMANN D, KOLLEWE C, MARTIN MU, BORASCHI D: The membrane form of the Type II IL-1 receptor accounts for inhibitory function. J. Immunol. (2000) 165:3350-3357.
111. BOURKE E, CASSETTI A, VILLA A et al.: IL-1 β scavenging by the Type II IL-1 decoy receptor in human neutrophils. J. Immunol. (2003) 170:5999-6005. (Pubitemid 36682580)
112. WANG J, ELEWAUT D, VEYS EM, VERBRUGGEN G: Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the activity of interleukin-1 and controls the homeostasis of the extracellular matrix of cartilage. Arthritis Rheum. (2003) 48:1281-1291.
113. MANTOVANI A, LOCATI M, V ECCHI A, SOZZANI S, ALLAVENA P: Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. (2001) 22:328-336.
114. CUI X, ROUHANI FN, HAWARI F, LEVINE SJ: Shedding of the Type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor Type 1 shedding. J. Immunol. (2003) 171:6814-6819.
115. DEBETS R, TIMANS JC, CHURAKOWA T et al.: IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J. Immunol. (2000) 165:4950-4956.
116. CHEUNG H, CHEN NJ, CAO Z et al.: Accessory protein-like is essential for IL-18-mediated signaling. J. Immunol. (2005) 174:5351-5357.
117. VERMOT-DESROCHES C, UBIGER O, GUENOT F et al.: Monoclonal antibodies specific for the IL-18 receptor. Cell. Immunol. (2005) 236:86-91.
118. KATO Z, JEE J, SHIKANO H et al.: The structure and binding mode of interleukin-18. Nat. Struct. Biol .(2003) 10:966-971. • Demonstrates the presence of three distinct sites on IL-18 that are important for receptor activation, two of which are involved in IL-18Rα binding and the third one in IL-18Rβ binding.
119. AZAM T, NOVICK D, BUFLER P et al.: Identification of a critical Ig-like domain in IL-18 receptor α and characterization of a functional IL-18 receptor complex. J. Immunol. (2003) 171:6574-6580.
120. KIM SH, AZAM T, YOON DY et al.: Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein. Proc. Natl. Acad. Sci. USA (2001) 98:3304-3309.
121. BORN TL, THOMASSEN E, BIRD TA, E SJ: Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J. Biol. Chem. (1998) 23:29445-29450.
122. WU C, SAKORAFAS P, MILLER R et al.: IL-18 receptor β-induced changes in the presentation of IL-18 binding sites affect ligand binding and signal transduction. J. Immunol. (2003) 170:5571-5577.
123. KUNIKATA T, TORIGOE K, USHIO S et al.: Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody. Cell. Immunol. (1998) 189:135-143.
124. CHAN WL, PEJNOVIC N, LEE CA, AL-ALI NA: Human IL-18 receptor and ST2L are stable and selective markers for the respective Type 1 and Type 2 circulating lymphocytes. J. Immunol. (2001) 167:1238-1244.
125. GUTZMER R, LANGER K, MOMMERT S et al.: Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J. Immunol. (2003) 171:6363-6371.
126. SARENEVA T, JULKUNEN I, MATIKAINEN S: IFN-α and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J. Immunol. (2000) 165:1933-1938. (Pubitemid 30648745)
127. THOMASSEN E, BIRD TA, RENSHAW BR, KENNEDY MK, SIMS JE: Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J. Interferon Cytokine Res. (1998) 18:1077-1088.
128. MOREL JCM, PARK CC, ZHU K et al.: Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J. Biol. Chem. (2002) 277:34679-34691.
129. LEE JK, KIM SH, LEWIS EC et al.: Differences in signaling pathways by IL-1β and IL-18. Proc. Natl. Acad. Sci. USA (2004) 101:8815-8820. • Shows that, in contrast to IL-1β, IL-18 signals primarily via the MAPK p38 pathway rather than NF-κB in human epithelial cells.
130. CHANDRASEKAR B, MUMMIDI S, VALENTE AJ et al.: The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J. Biol. Chem. (2005) 280:26263-26277.
131. YOO JK, KWON H, KHIL LY et al.: IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J. Immunol. (2005) 175:8280-8286.
132. H1 cytokine response. Immunity (1999) 10:127-136.
133. KIM SH, EISENSTEIN M, REZNIKOV L et al.: Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA (2000) 97:1190-1195. • Initial characterisation of IL-18BP isoforms.
134. DINARELLO CA, NOVICK D, RUBINSTEIN M, LONNEMANN G: Interleukin 18 and interleukin 18 binding protein: possible role in immunosuppression of chronic renal failure. Blood Purif. (2003) 21:258-270. (Pubitemid 36649376)
135. PAULUKAT J, BOSMANN M, NOLD M et al.: Expression and release of IL-18 binding protein in response to IFN-γ. J. Immunol. (2001) 167:7038-7043.
136. MOLLER B, PAULUKAT J, NOLD M et al.: Interferon-γ induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology (2003) 42:442-445. (Pubitemid 36367535)
137. LOVENBERG TW, CROWE PD, LIU C et al.: Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2). J. Neuroimmunol. (1996) 70:113-122. (Pubitemid 26345919)
138. PARNET P, GARKA KE, BONNERT TP, DOWER SK, SIMS JE: IL-1Rrp is a novel receptor-like molecule similar to the Type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J. Biol. Chem. (1996) 271:3967-3970.
139. TRAJKOVIC V, SWEET MJ, XU D: T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. (2004) 15:87-95.
140. H1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur. J. Immunol. (2002) 32:2979-2987.
141. SHIMIZU M, MATSUDA A, YANAGISAWA K et al.: Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum. Mol. Genet. (2005) 14:2919-2927.
142. BRINT EK, XU D, LIU H et al.: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immun. (2004) 5:373-379.
143. TAJIMA S, OSHIKAWA K, TOMINAGA S, SUGIYAMA Y: The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest (2003) 124:1206-1214.
144. BRUNNER M, KRENN C, ROTH G et al.: Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. (2004) 30:1468-1473.
145. SHIMPO M, MORROW DA, WEINBERG EO et al.: Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation (2004) 109:2186-2219.
146. LEUNG BP, XU D, CULSHAW S, MCINNES IB, LIEW FY: A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. (2004) 173:145-150.
147. THOMASSEN E, RENSHAW BR, SIMS JE: Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine (1999) 11:389-399.
148. WALD D, QIN J, ZHAO Z et al.: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immun.(2003) 4:920-927.
149. GARLANDA C, RIVA F, POLENTARUTTI N et al.: Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl. Acad. Sci. USA (2004) 101:3522-3526.
150. QIN J, QIAN Y, YAO J, CUI G, LI X: SIGIRR inhibits IL-1R-and TLR4-mediated signaling through different mechanisms. J. Biol. Chem. (2005) 280:25233-25241.
151. CARRIE A, JUN L, BIENVENU T et al.: A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nat. Genet. (1999) 23:25-31.
152. BORN TL, SMITH DE, GARKA KE et al.: Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family. Delineation of a new class of IL-1R-related proteins based on signaling. J. Biol. Chem. (2000) 275:29946-29954.
153. JIN H, GARDNER RJ, VISWESVARAIAH R, MUNTONI F, ROBERTS RG: Two novel members of the interleukin-1 receptor gene family, one deleted in Xp22.1-Xp21.3 mental retardation. Eur. J. Hum. Genet. (2000) 8:87-94.
154. SANA TR, DEBETS R, TIMANS JC, BAZAN JF, KASTELEIN RA: Computational identification, cloning, and characterization of IL-1R9, a novel interleukin-1 receptor-like gene encoded over an unusually large interval of human chromosome Xq22.2-q22.3. Genomics (2000) 69:252-262.
155. KHAN JA, BRINT EK, O'NEILL LA, TONG L: Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J. Biol. Chem. (2004) 279:31664-31670. (Pubitemid 39037837)
156. BAHI N, FRIOCOURT G, CARRIE A et al.: IL1 receptor accessory protein like, a protein involved in X-linked mental retardation, interacts with Neuronal Calcium Sensor-1 and regulates exocytosis. Hum. Mol. Genet. (2003) 12:1415-1425.
157. COX A, CAMP NJ, NICKLIN MJH, DI GIOVINE FS, DUFF GW: An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am. J. Hum. Genet. (1998) 62:1180-1188.
158. DU Y, DODEL RC, EASTWOOD BJ et al.: Association of an interleukin 1 polymorphism with Alzheimer's disease. Neurology (2000) 55:480-484.
159. GRIMALDI LM, CASADEI VM, FERRI C et al.: Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism. Ann. Neurol. (2000) 47:361-365. (Pubitemid 30141846)
160. GREEN EK, HARRIS JM, LEMMON H et al.: Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology (2002) 58:1566-1568. (Pubitemid 34552974)
161. SERIPA D, MATERA MG, DAL FORNO G et al.: Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiol. Aging (2005) 26:455-464.
162. HAYES A, GREEN EK, PRITCHARD A et al.: A polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry (2004) 75:1475-1477.
163. GRIFFIN WS: Inflammation and neurodegenerative diseases. Am. J. Clin. Nutr. (2006) 83:470S-474S.
164. JOUVENNE P, CHAUDHARY A, BUCHS N et al.: Possible genetic association between interleukin-1α gene polymorphism and the severity of chronic polyarthritis. Eur. Cytokine Netw. (1999) 10:33-36.
165. CAMP NJ, COX A, DI GIOVINE FS et al.: Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun. (2005) 6:467-471. •• This study demonstrates a significant association between the composite genotype across IL1A (+4845) and IL1B (+3954) and the response to anakinra treatment in RA patients.
166. KIMURA R, NISHIOKA T, SOEMANTRI A, ISHIDA T: Cis-acting effect of the IL1B C-31T polymorphism on IL-1 β mRNA expression. Genes Immun. (2004) 5:572-575.
167. HALL SK, PERREGAUX DG, GABEL CA et al.: Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 β protein. Arthritis Rheum. (2004) 50:1976-1983.
168. WANG ZC, YUNIS EJ, DE LOS SANTOS MJ et al.: T helper 1-type immunity to trophoblast antigens in women with a history of recurrent pregnancy loss is associated with polymorphism of the IL1B promoter region. Genes Immun. (2002) 3:38-42.
169. LICASTRO F, VEGLIA F, CHIAPPELLI M, GRIMALDI LM, MASLIAH E: A polymorphism of the interleukin-1 β gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer's disease. Neurobiol. Aging (2004) 25:1017-1022.
170. CHEN H, WILKINS LM, AZIZ N et al.: Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum. Mol. Genet. (2006) 15:519-529. • Identifies four IL1B promoter region single nucleotide polymorphisms and demonstrates that the effect of individual polymorphisms on gene transcription depends on allelic variations in the other polymorphic sites.
171. WITKIN SS, GERBER S, LEDGER WJ: Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin. Infect. Dis. (2002) 34:204-209. (Pubitemid 34028353)
172. VIJGEN L, VAN GYSEL M, RECTOR A et al.: Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. Genes Immun. (2002) 3:400-406. (Pubitemid 41656538)
173. DEWBERRY RM, CROSSMAN DC, FRANCIS SE: Interleukin-1 receptor antagonist (IL-1RN) genotype modulates the replicative capacity of human endothelial cells. Circ. Res. (2003) 92:1285-1287.
174. REDLITZ KH, YAMSHCHIKOV VF, COMINELLI F: Differential contribution of IL-1Ra isoforms to allele-specific IL-1Ra mRNA accumulation. J. Interferon Cytokine Res. (2004) 24:253-260. (Pubitemid 38526785)
175. CARTER MJ, JONES S, CAMP NJ et al.: Functional correlates of the interleukin-1 receptor antagonist gene polymorphism in the colonic mucosa in ulcerative colitis. Genes Immun. (2004) 5:8-15.
176. LIND H, ZIENOLDDINY S, RYBERG D et al.: Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1β gene. Lung Cancer (2005) 50:285-290. (Pubitemid 43300628)
177. MAKSYMOWYCH WP, REEVE JP, REVEILLE JD et al.: High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of- flight mass spectrometry. Arthritis Rheum. (2003) 48:2011-2018.
178. SMITH AJ, KEEN LJ, BILLINGHAM MJ et al.: Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: association with knee osteoarthritis. Genes Immun. (2004) 5:451-460. •• Supports the concept that polymorphic IL-1 haplotypes or extended haplotypes provide better genetic markers of transcriptional activity and disease association than single locus polymorphisms as exemplified by the case of knee OA.
179. TIMMS AE, CRANE AM, SIMS AM et al.: The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am. J. Hum. Genet. (2004) 75:587-595.
180. CHOU CT, TIMMS AE, WEI JC et al.: Replication of association of IL-1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann. Rheum. Dis. (2005) (In Press).
181. SAMANI NJ, BURTON P, MANGINO M et al.: A genomewide linkage study of 1,933 families affected by premature coronary artery disease: The British Heart Foundation (BHF) Family Heart Study. Am. J. Hum. Genet. (2005) 77:1011-1020.
182. TIRET L, GODEFROY T, LUBOS E et al.: Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation (2005) 112:643-650.
183. NOVAK N, KRUSE S, POTRECK J et al.: Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. J. Allergy Clin. Immunol. (2005) 115:828-833. (Pubitemid 40460861)
184. IMBODEN M, NICOD L, NIETERS A et al.: The common G-allele of interleukin-18 single-nucleotide polymorphism is a genetic risk factor for atopic asthma. Clin. Exp. Allergy (2006) 36:211-218.
185. ARIMITSU J, HIRANO T, HIGA S et al.: IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem. Biophys. Res. Commun. (2006) 342:1413-1416.
186. DINARELLO CA: Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol. (2004) 4:378-385. • An up-to-date review of the various strategies that are currently explored to inhibit the bioactivity of IL-1 for the treatment of inflammation.
187. ASHWELL S: Caspases: recent advances in small molecule inhibitors. Expert Opin. Ther. Patents (2001) 11:1593-1603. (Pubitemid 33019606)
188. LINTON SD: Caspase inhibitors: a pharmaceutical industry perspective. Curr. Top. Med. Chem. (2005) 5:1697-1717. • This review includes a section on recent developments in the discovery of chemical inhibitors of caspase-1.
189. O'NEIL SV, WANG Y, LAUFERSWEILER MC et al.: Synthesis and evaluation of novel 8,6-fused bicyclic peptidomimetic compounds as interleukin-1β converting enzyme inhibitors. Bioorg. Med. Chem. Lett (2005) 15:5434-5438.
190. LAUFERSWEILER MC, WANG Y, SOPER DL et al.: Synthesis and evaluation of tricyclic pyrrolopyrimidinones as dipeptide mimetics: inhibition of interleukin-1β-converting enzyme. Bioorg. Med. Chem. Lett. (2005) 15:4322-4326.
191. OPPONG KA, ELLIS CD, LAUFERSWEILER MC et al.: Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1β synthesis. Bioorg. Med. Chem. Lett (2005) 15:4291-4294.
192. FAHR BT, O'BRIEN T, PHAM P et al.: Tethering identifies fragment that yields potent inhibitors of human caspase-1. Bioorg. Med. Chem. Lett (2006) 16:559-562.
193. STACK JH, BEAUMONT K, LARSEN PD et al.: IL-1-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. (2005) 175:2630-2634.
194. LABASI JM, PETRUSHOVA N, DONOVAN C et al.: Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. (2002) 168:6436-6445. •• This study demonstrates that genetic ablation of P2X7R expression in mice reduced the incidence and severity of collagen-induced arthritis.
195. 7R expression in mice abrogates inflammatory and neuropathic responses as a result of reduced IL-1β production.
196. BAXTER A, BENT J, BOWERS K et al.: Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg. Med. Chem. Lett (2003) 13:4047-4050. (Pubitemid 37338445)
197. 7 receptor antagonists. Bioorg. Med. Chem. Lett (2003) 13:4043-4046.
198. 7 receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15:435-438.
199. PERREGAUX DG, MCNIFF P, LALIBERTE R et al.: Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J. Pharmacol. Exp. Ther. (2001) 299:187-197.
200. LALIBERTE RE, PERREGAUX DG, HOTH LR et al.: Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1β posttranslational processing. J. Biol. Chem. (2003) 278:16567-16578. • Shows that diarylsulfonylurea inhibitors of ATP-induced IL-1β post-translational processing interact with glutathione S-transferase omega 1-11, which may represent the mechanism of action of these compounds.
201. YIN ZL, DAHLSTROM JE, LE COUTEUR DG, BOARD PG: Immunohistochemistry of omega class glutathione-S-transferase in human tissues. J. Histochem. Cytochem. (2001) 49:983-987.
202. ICHIKAWA K, HIRAI H, ISHIGURO M et al.: Novel cytokine production inhibitors produced by a basidiomycete, Marasmiellus sp. J. Antibiot. (2001) 54:703-709. (Pubitemid 32962795)
203. ICHIKAWA K, HIRAI H, ISHIGURO M et al.: Cytokine production inhibitors produced by a fungus, Oidiodendron griseum. J. Antibiot. (2001) 54:697-702. (Pubitemid 32962794)
204. MATSUDA T, AOKI T, KOSHI T, OHKUCHI M, SHIGYO H: Synthesis and bioactivities of novel 5,6-bis(4-methoxyphenyl)-2H-pyridazin-3-one derivatives: inhibitors of interleukin-1 β (IL-1β) production. Bioorg. Med. Chem. Lett (2001) 11:2373-2375. (Pubitemid 32781702)
205. MATSUDA T, AOKI T, OHGIYA T et al.: Synthesis and bioactivities of novel pyridazine derivatives: inhibitors of interleukin-1 β (IL-1β) production. Bioorg. Med. Chem. Lett (2001) 11:2360-2372.
206. VERBRUGGEN G: Chondroprotective drugs in degenerative joint diseases. Rheumatology (2006) 45:129-138.
207. BESSIS N, GUERY L, MANTOVANI A et al.: The Type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur. J. Immunol. (2000) 30:867-875.
208. SMEETS RL, JOOSTEN LA, ARNTZ OJ et al.: Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum. (2005) 52:2202-2211. • This paper reports evidence that sIL-1RAcP and IL-1ra antagonised the action of IL-1 differently in a CIA mouse model. Both ameliorated the arthritis and reduced anti-collagen antibodies, but only IL-1ra inhibited T cell immunity.
209. ECONOMIDES AN, CARPENTER LR, RUDGE JS et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9:47-52. • Describes the designing of 'cytokine traps' that consist of fusions between the constant region of IgG and the extracellular domains of two distinct cytokine receptor components.
210. GABAY C: IL-1 trap. Regeneron/Novartis. Curr. Opin. Invest. Drugs (2003) 4:593-597.
211. CANNA S, GELABERT A, AKSENTIJEVICH I et al.: Treatment of 4 patients with cryopyrin-associated periodic syndromes with the long acting IL-1 inhibitor IL-1 trap. Annual Meeting European Congress of Rheumatology, European League Against Rheumatism. Vienna, Austria (2005) Abstr. OP0154. • The data presented in this abstract show that IL-1 trap is effective for the treatment of autoinflammatory disorders.
212. RECTENWALD JE, MOLDAWER LL, HUBER TS, SEEGER JM, OZAKI CK: Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation (2000) 102:1697-1702.
213. CHI H, MESSAS E, LEVINE RA, GRAVES DT, AMAR S: Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation (2004) 110:1678-1685.
214. WAEHRE T, YNDESTAD A, SMITH C et al.: Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation (2004) 109:1966-1972.
215. LU J, WITCHER DR, WHITE MA et al.: IL-1β epitope mapping using site-directed mutagenesis and hydrogen-deuterium exchange mass spectrometry analysis. Biochemistry (2005) 44:11106-11114.
216. BERTIN-MAGHIT SM, CAPINI CJ, BESSIS N et al.: Improvement of collagen-induced arthritis by active immunization against murine IL-1β peptides designed by molecular modelling. Vaccine (2005) 23:4228-4235.
217. FLEISCHMANN R, STERN R, IQBAL I: Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. (2004) 4:1333-1344. • Along with reference 18 reviews the clinical studies of anakinra in RA and shows that it has a favourable safety profile and beneficial activity.
218. BUCH MH, BINGHAM SJ, SETO Y et al.: Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade. Arthritis Rheum. (2004) 50:725-728. • Demonstrates that RA patients who failed to respond to TNF-α blockade also did not respond to anakinra.
219. FLEISHMANN RM: Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-α agents. Clin. Exp. Rheumatol. (2002) 20:S35-S41.
220. VERBSKY JW, WHITE AJ: Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. (2004) 31:2071-2075. • First evidence that anakinra treatment has a marked beneficial effect in therapy resistant systemic onset juvenile RA.
221. PASCUAL V, ALLANTAZ F, ARCE E, PUNARO M, BANCHEREAU J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. (2005) 201:1479-1486. • This study provides evidence that IL-1 is a major mediator of inflammation in systemic onset juvenile idiopathic arthritis as anakinra treatment dramatically ameliorated the disease.
222. FITZGERALD AA, LECLERCQ SA, YAN A, HOMIK JE, DINARELLO CA: Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. (2005) 52:1794-1803. (Pubitemid 40852888)
223. HAWKINS PN, LACHMANN HJ, AGANNA E, MCDERMOTT MF: Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. (2004) 50:607-612. •• Shows that the clinical and serological evidence of active inflammatory disease resolved rapidly and completely during treatment with anakinra in Muckle-Wells syndrome, an autoinflammatory disorder associated with cryopyrin dysfunction.
224. LOVELL DJ, BOWYER SL: Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal onset multisystem inflammatory disease. Arthritis Rheum. (2005) 52:1283-1286.
225. DIERSELHUIS MP, FRENKEL J, WULFFRAAT NM, BOELENS JJ: Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (2005) 44:406-408.
226. EMSLEY HC, SMITH CJ, GEORGIOU RF et al.: A randomised Phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry (2005) 76:1366-1372. • The data from this study suggest that anakinra was safe and well tolerated and improved markers of biological activity when administered within 6 h of symptom onset in patients with acute stroke.
227. CHEVALIER X, GIRAUDEAU B, CONROZIER T et al.: Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol. (2005) 32:1317-1323.
228. CHEVALIER X, GOUPILLE P, BEAULIEU AD et al.: Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of anakinra (KineretR) in patients with osteoarthritis of the knee. ACR Meeting (2005) Abstract 1339/115.
229. FRISBIE DD, GHIVIZZANI SC, ROBBINS PD, EVANS CH, MCILWRAITH CW: Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther. (2002) 9:12-20. • Shows that the intra-articular overexpression of the gene for IL-1ra resulted in significant improvement in clinical and histological parameters in an equine model of OA.
230. HAUPT JL, FRISBIE DD, MCILWRAITH CW et al.: Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J. Orthop. Res. (2005) 23:118-126.
231. EVANS CH, ROBBINS PD, GHIVIZZANI SC et al.: Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc. Natl. Acad. Sci. USA (2005) 102:8698-8703. •• Demonstrates that it is possible to safely transfer the IL-1ra gene to human rheumatoid joints and obtain intra-articular expression of the transgene.
232. LE MAITRE CL, FREEMONT AJ, HOYLAND JA: A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration. Int. J. Exp. Pathol. (2006) 87:17-28.
233. MOORE EE, BENDELE AM, THOMPSON DL et al.: Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage (2005) 13:623-631.
234. NESIC O, XU GY, MCADOO D et al.: IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J. Neurotrauma (2001) 18:947-956.
235. MAURY CP, LILJESTROM M, LAIHO K et al.: Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1β-511 promoter gene and raised levels of interleukin-1β and interleukin-18. J. Intern. Med. (2004) 256:145-152.
236. FREDERICKS ZL, FORTE C, CAPUANO IV et al.: Identification of potent human anti-IL-1RI antagonist antibodies. Protein Engl. Des. Sel. (2004) 17:95-106.
237. DAYER JM, MOLNARFI N, BURGER D: From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation? Expert Opin. Biol. Ther. (2005) 5:S83-S96. • This review discusses the advantages and disadvantages of targeting extracellular versus intracellular mechanisms of cytokine action for the treatment of inflammatory diseases.
238. BURNS K, JANSSENS S, BRISSONI B et al.: Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. (2003) 197:263-268.
239. BARTFAI T, BEHRENS MM, GAIDAROVA S et al.: A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. USA (2003) 100:7971-7976. •• Describes the synthesis of a low molecular weight TIR mimic capable of disrupting the interaction between MyD88 and IL-1RI. This compound inhibited IL-1β signaling and attenuated the fever response induced by IL-1β.
240. LOIARRO M, SETTE C, GALLO G et al.: Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-κB. J. Biol. Chem. (2005) 280:15809-15814. •• Shows that a cell permeable epta-peptide derived from the TIR domain of MyD88 significantly reduced IL-1 signaling as assessed by activation of NF-κB.
241. LI C, ZIENKIEWICZ J, HAWIGER J: Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1β signaling pathway. J. Biol. Chem. (2005) 280:26152-26159.
242. MEDVEDEV AE, THOMAS K, AWOMOYI A et al.: Cutting edge: expression of IL-1 receptor-associated kinase-4 (IRAK-4) proteins with mutations identified in a patient with recurrent bacterial infections alters normal IRAK-4 interaction with components of the IL-1 receptor complex. J. Immunol. (2005) 174:6587-6591.
243. KOBAYASHI T, WALSH MC, CHOI Y: The role of TRAF6 in signal transduction and the immune response. Microbes Infect. (2004) 6:1333-1338. (Pubitemid 39539732)
244. KARIN M, YAMAMOTO Y, WANG QM: The IKK NF-κ B system: a treasure trove for drug development. Nat. Rev. Drug Discov. (2004) 3:17-26. (Pubitemid 38088695)
245. COISH PDG, WICKENS PL, LOWINGER TB: Small molecule inhibitors of IKK kinase activity. Expert Opin. Ther. Patents (2006) 16:1-12. (Pubitemid 43056399)
246. DOMINGUEZ C, TAMAYO N, ZHANG D: p38 Inhibitors: beyond pyridinylimidazoles. Expert Opin. Ther. Patents (2005) 15:801-816.
247. ZHU M, XU X, LIU H et al.: Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant. J. Med. Microbiol. (2003) 52:223-228.
248. LIU B, MORI I, HOSSAIN MJ et al.: Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J. Gen. Virol. (2004) 85:423-428.
249. VAN DER SLUIJS KF, VAN ELDEN LJ, ARENS R et al.: Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza A virus. Immunology (2005) 114:112-120.
250. CUSUMANO V, MIDIRI A, CUSUMANO VV et al.: Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates. Infect. Immun. (2004) 72:295-300.
251. GOLAB J, STOKLOSA T: Technology evaluation: SB-485232, GlaxoSmithKline. Curr. Opin. Mol. Ther. (2005) 7:85-93.
252. LEWIS N, GOLLOB J, COHEN R et al.: Phase I dose escalation study to assess tolerability and pharmacokinetics of recombinant human IL-18 (rhIL-18) administered as fourteen daily subcutaneous injections in patients with solid tumors. J. Clin. Oncol. (2004) 22:Abstr. 2591.
253. ROBERTSON MJ, MIER J, LOGAN T et al.: Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors. J. Clin. Oncol. (2004) 22:Abstr. 2553.
254. MARSHALL DJ, RUDNICK KA, MCCARTHY SG et al.: Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine (2005) 24:244-253.
255. WIENHOLD D, ARMENGOL E, MARQUARDT A et al.: Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination. Vet. Res. (2005) 36:571-587.
256. LEE KA, CHO KJ, KIM SH et al.: IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response. Cancer Lett. (2005) 229:261-270. • Demonstrates that a single point mutation E42A in IL-18 renders the cytokine resistant to inhibition by human papillomavirus E6 and E7 oncogenes without affecting its IFN-γ-inducing activity.
257. YAMAMOTO Y, KATO Z, MATSUKUMA E et al.: Generation of highly stable IL-18 based on a ligand-receptor complex structure. Biochem. Biophys. Res. Commun. (2004) 317:181-186. • Demonstrates that replacing cysteine residues to serine in IL-18 resulted in a mutant protein with high stability that retained biological activity even after oxidation.
258. FELDERHOFF-MUESER U, SCHMIDT OI, OBERHOLZER A, BUHRER C, STAHEL PF: IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci. (2005) 28:487-493.
259. MCINNES IB, LIEW FY, GRACIE JA: Interleukin-18: a therapeutic target in rheumatoid arthritis? Arthritis Res. Ther. (2005) 7:38-41. (Pubitemid 40214526)
260. DINARELLO CA: Targeting interleukin 18 with interleukin 18 binding protein. Ann. Rheum. Dis. (2000) 59S1:17-20.
261. BANDA NK, VONDRACEK A, KRAUS D et al.: Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol. (2003) 170:2100-2105. • Shows that IL-18BP suppressed arthritis in a mouse CIA model by reducing cell-mediated and humoral immunity to collagen as well as decreasing the production of pro-inflammatory cytokines.
262. DINARELLO CA, FANTUZZI G: Interleukin-18 and host defense against infection. J. Infect. Dis. (2003) 187:S370-S384. (Pubitemid 36724511)
263. REMICK DG, BOLGOS GE, SIDDIQUI J: Inflammatory status in sepsis alters efficacy of interleukin-18 binding protein therapy. Crit. Care Med. (2003) 31:2096-2101.
264. PLITZ T, SAINT-MEZARD P, SATHO M et al.: IL-18 binding protein protects against contact hypersensitivity. J. Immunol. (2003) 171:1164-1171.
265. REZNIKOV LL, KIM SH, ZHOU L et al.: The combination of soluble IL-18Rα and IL-18Rβ chains inhibits IL-18-induced IFN-γ. J. Interferon Cytokine Res. (2002) 22:593-601.
266. PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. (2001) 108:1825-1832.
267. SIEGMUND B, FANTUZZI G, RIEDER F et al.: Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281:R1264-R1273. (Pubitemid 32948260)
268. H1 responses to peripheral myelin antigen. J. Neuropathol. Exp. Neurol. (2002) 61:614-622.
269. HAMASAKI T, HASHIGUCHI S, ITO Y et al.: Human anti-human IL-18 antibody recognizing the IL-18-binding site 3 with IL-18 signaling blocking activity. J. Biochem. (2005) 138:433-442. • Description of a human anti-IL-18 single chain antibody that blocks the bioactivity of IL-18 by binding to its IL-18Rβ interacting site.
270. STARUCH MJ, WOOD DD: The adjuvanticity of interleukin-1 in vivo. J. Immunol. (1983) 130:2191-2194. • Pioneering work demonstrating that IL-1 has immuno-enhancing activities in vivo.
271. MARTINON F, AGOSTINI L, MEYLAN E, TSCHOPP J: Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. (2004) 14:1929-1934.
272. HOLLIGER P, HUDSON PJ: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. (2005) 23:1626-1636.
273. ROSES AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. (2004) 5:645-656.
274. WOLDBAEK PR, SANDE JB, STROMME TA et al.: Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am. J. Physiol. Heart Circ. Physiol. (2005) 289:H708-H714.
275. REUTER BK, PIZARRO TT: Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur. J. Immunol. (2004) 34:2347-2355.
276. SIMS J, TOWNE J, BLUMBERG H: Eleven IL-1 family members in inflammatory skin disease. Ernst Schering Res. Found. Workshop (2006) 56:187-191.
277. PICARD C, PUEL A, BONNET M, AL E: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science (2003) 299:2076-2079.
278. MILLER LS, O'CONNELL RM, GUTIERREZ MA et al.: MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity (2006) 24:79-91.
279. http://www.vrtx.com • Vertex Pharmaceuticals Incorporated, principally focused on viral diseases, inflammation, autoimmune diseases and cancer.
280. http://www.astrazeneca.com • Astrazeneca, one of the world's leading pharmaceutical companies.
281. http://www.kowa.co.jp • Kowa, a Japanese company involved in manufacturing and trading in the fields of pharmaceutical, life science and information technology, textiles, machinery and various consumer products.
282. http://www.regeneron.com • Regeneron, a biopharmaceutical company that has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases and inflammation.
283. http://www.novartis.com • Novartis, involved in pharmaceuticals, sandoz and consumer health.
284. http://www.ucb-group.com • UCB, biopharmaceutical company involved in CNS disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology.
285. http://www.amgen.com • Amgen, a human therapeutics company in the biotechnology industry.
286. http://www.roche.com • Roche, a healthcare company involved in prevention, diagnosis and treatment of disease.
287. http://www.Serono.com • Serono, a biotechnology company.